{"doi":"10.1200/jco.2004.22.14_suppl.655","title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","abstract":null,"journal":null,"year":null,"id":638730,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","abstract":"655 Background: HER-2 overexpression, a predictive marker of tumor aggressiveness and responsiveness to therapy, occurs in 20–30% of breast cancer. Although breast cancer is a heterogeneous disease, HER-2 evaluation is done in primary tumor. HER-2 was measured in both primary and metastases to evaluate whether heterogeneity between primary breast cancer and metastatic sites exists in HER-2 overexpression and the effect of HER-2 on treatment decisions. Methods: Biopsies from primary breast cancer and corresponding metastases of 58 patients were studied. HER-2 overexpression was evaluated immunohistochemically (IHC) in all primary and metastatic sites using CB11 monoclonal antibody and DAKO Hercept-Test scoring. Positive results were confirmed by fluorescence in situ hybridization (FISH). Results: Median time from primary tumor to diagnosis of metastases was 4.5 years (range 1–12 years). Discordance in HER-2 overexpression between primary and metastatic sites was 14% (8 of 58 patients). In 1 patient (2%), HER-2 was negative in metastasis but positive in primary. In 7 (12%) patients HER-2 was positive in metastases and negative in primary. Concordance in HER-2 in primary and metastatic sites was found in 50 (86%) of patients (95% CI: 70.6–94.4). Three patients with HER-2 positive in metastatic sites and negative in primary responded to trastuzumab therapy. Conclusions: HER-2 is an important predictive biological marker for treatment of breast cancer. Possible discordance of HER-2 overexpression between primary and metastatic sites should be considered when making treatment decisions of metastatic sites. No significant financial relationships to disclose.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W2328066855","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://ascopubs.org/doi/pdfdirect/10.1200/jco.2004.22.90140.655","host_type":"publisher"},{"url":"https://doi.org/10.1200/jco.2004.22.14_suppl.655","host_type":"journal"}],"fields_of_study":["HER2/EGFR in Cancer Research","Monoclonal and Polyclonal Antibodies Research","Cancer Treatment and Pharmacology"],"mesh_terms":[],"keywords":["Medicine","Metastatic breast cancer","Concordance","Breast cancer","Primary tumor","Trastuzumab","Metastasis","Oncology","Immunohistochemistry","CA15-3","Cancer","Internal medicine","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T21:18:21.776693Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}